Skip to content

Impact of Preoperative Single Corticosteroid Flash on Morbidity After Colorectal Resection: Monocentric Prospective Pilot Study

Impact of Preoperative Single Corticosteroid Flash on Morbidity After Colorectal Resection: Monocentric Prospective Pilot Study

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03437746
Acronym
CORTICOLON
Enrollment
78
Registered
2018-02-19
Start date
2018-03-01
Completion date
2021-11-24
Last updated
2026-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elective Colorectal Surgery

Brief summary

Complications due to infection after colorectal surgery are frequent, affecting up to 25% of patients. Infection increases mortality, lengthens hospital stays, increases costs and decreases long term survival for cancer patients. Perioperative inflammation leads to hypercatabolism, denutrition and immunosuppression, all of which are associated to postoperative infection. Data from various sources suggests that modulating perioperative inflammatory response through the injection of corticosteroids would benefit the patient by reducing the number of postoperative complications after major surgery. Pre- or perioperative intravenous administration of a single corticosteroid flash is a means of modulating systemic inflammation that has been suggested for numerous types of surgeries, including pancreatic surgery. The objective of this study is to assess whether a preoperative single corticosteroid flash (methylprednisolone: 20 mg/kg IV at anesthetic induction) reduces the risk of serious complications after elective colorectal surgery.

Interventions

DRUGinjection of methylprednisolone at anesthetic induction

intravenous administration : 20 mg/kg, over 30 minutes at anesthetic induction

BIOLOGICALBlood samples

Blood samples (D0, D1, D2, D3, D4)

Sponsors

Centre Hospitalier Universitaire Dijon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patient * Patient undergoing elective colorectal surgery (diverticulitis, malignant or benign tumor, inflammatory intestinal disease, re-establishing continuity, endometriosis, or other) * Bowel continuity is restored immediately after surgery, with or without a protective stoma. * Patient with proper understanding who has been informed about the study, and who has consented to being part of the study

Exclusion criteria

* Adult under guardianship * Patient who is not covered under the national health system * Women who are pregnant or breastfeeding * Colorectal resection with concomitant hyperthermic intraperitoneal chemotherapy * Patient under long term corticosteroid therapy * Preoperative natremia \> 147 mmol/L * Hypokalemia (\< 3,3 mmol/L) * Patient with a contraindication to Methylprednisolone Mylan® : * Active infection * Active viral disease (namely hepatitis, herpes, varicella, shingles), * A psychotic condition that is not currently treated with medication, * Vaccination with a live vaccine or live attenuated within the last 3 months, * Hypersensitivity to methylprednisolone or to any of the excipients found in Methylprednisolone Mylan®

Design outcomes

Primary

MeasureTime frame
Frequency of postoperative complications, occuring up to 30 days post-operativelyDay 30

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026